2401 4TH AVE., SEATTLE, WA
Delivers Compelling 86% Clinical Benefit Rate and No CRS as Evaluable AML Patient Data increases by Nearly 50%
Stockholder Vote Results from Aptevo Therapeutics Special Meeting
Announces Executive Leadership Transitions to Support Next Phase of Growth
Secures $60 Million Equity Line of Credit to Support Multispecific Portfolio Advancement, Increase Strategic Optionality
Aptevo Therapeutics Inc. Approves Reverse Stock Split Amendment
Highlights Compelling Safety and Strong Remission Rates for Mipletamig in Frontline AML at ASH 2025
Reports 3Q25 Financial Results And Provides A Business Update
Material Contracts, Material Modifications to Rights of Security Holders
Q3
Q2
Q1
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(4)
S-1
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Correspondence
Submission Upload